Humanized anti-PD-L1 antibodies
US11643466B2 · kind B2 · utility
0Cited by
2References
18Claims
0Family size
Assignee
Inventor
Key dates
| Filing date | Aug 19, 2021 |
| Grant date | May 9, 2023 |
| Priority date | — |
| Expiry date | Aug 19, 2041 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/94
- WIPO fieldBiotechnology
- WIPO sectorChemistry
Abstract
The present disclosure provides isolated binding molecules that bind to and blocks PD-L1, vectors comprising a nucleic acid molecules encoding an amino acid sequence of the binding molecules, host cells containing the vectors, methods of making the binding molecules, pharmaceutical compositions containing the binding molecules, and methods of using such antibodies, antibody fragments and derivatives and polypeptides, including methods of treating a disease requiring stimulation of immune responses including cancer.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.